- Home
- SNDX vs CRTO Comparison
SNDX vs CRTO Comparison
Compare SNDX & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- CRTO
- Stock Information
- Founded
- SNDX 2005
- CRTO 2005
- Country
- SNDX United States
- CRTO France
- Employees
- SNDX N/A
- CRTO N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- CRTO Advertising
- Sector
- SNDX Health Care
- CRTO Consumer Discretionary
- Exchange
- SNDX Nasdaq
- CRTO Nasdaq
- Market Cap
- SNDX 1.3B
- CRTO 1.1B
- IPO Year
- SNDX 2016
- CRTO 2013
- Fundamental
- Price
- SNDX $19.91
- CRTO $19.75
- Analyst Decision
- SNDX Strong Buy
- CRTO Buy
- Analyst Count
- SNDX 12
- CRTO 9
- Target Price
- SNDX $36.92
- CRTO $38.67
- AVG Volume (30 Days)
- SNDX 3.0M
- CRTO 470.9K
- Earning Date
- SNDX 11-03-2025
- CRTO 10-29-2025
- Dividend Yield
- SNDX N/A
- CRTO N/A
- EPS Growth
- SNDX N/A
- CRTO 83.79
- EPS
- SNDX N/A
- CRTO 3.00
- Revenue
- SNDX $111,304,000.00
- CRTO $1,956,800,000.00
- Revenue This Year
- SNDX $636.61
- CRTO N/A
- Revenue Next Year
- SNDX $114.95
- CRTO $1.84
- P/E Ratio
- SNDX N/A
- CRTO $6.63
- Revenue Growth
- SNDX 595.65
- CRTO 0.53
- 52 Week Low
- SNDX $8.58
- CRTO $19.15
- 52 Week High
- SNDX $20.08
- CRTO $47.27
- Technical
- Relative Strength Index (RSI)
- SNDX 72.56
- CRTO 38.95
- Support Level
- SNDX $16.75
- CRTO $19.15
- Resistance Level
- SNDX $20.08
- CRTO $20.59
- Average True Range (ATR)
- SNDX 1.23
- CRTO 0.85
- MACD
- SNDX 0.40
- CRTO -0.18
- Stochastic Oscillator
- SNDX 97.58
- CRTO 15.68
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.